ADICET-ADI-001-LTFU
Phase N/A
OPEN TO ACCRUAL
Long-Term Follow-Up Protocol for Subjects Treated with Adicet Allogeneic Gamma Delta CAR T Cell Investigational Products
CAELUM-CAEL101-301
Phase III
OPEN TO ACCRUAL *
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis
CIBMTR-10-CBA
Phase N/A
OPEN TO ACCRUAL
A Multicenter Access And Distribution Protocol For Unlicensed Cryopreserved Cord Blood Units (CBUs) For Transplantation In Pediatric And Adult Patients With Hematologic Malignancies And Other Indications
IIT-ABEDIN-PTCY-RUX-GVHD
Phase II
OPEN TO ACCRUAL
A Phase II Trial of De-escalated PTCy and Ruxolitinib for GVHD Prophylaxis in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT
IIT-HAMADANI-FLU-MEL-TBI
Phase II
OPEN TO ACCRUAL
A Phase II, Open-Label Study of Propylene Glycol-Free Melphalan for Injection (EVOMELA®) in Combination with Fludarabine and Total-Body, Irradiation-Based, Reduced-Intensity Conditioning for Haploidentical Transplantation
WEILLCORNELL-AMY2006-DPD
Phase II
OPEN TO ACCRUAL
Daratumumab, Pomalidomide and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab